[Efficacy and clinical remission in patients with severe asthma and blood eosinophil counts ≥150 cells/μl treated with benralizumab: a sub-analysis of the Phase 3 MIRACLE study].
Year: 2025
Type: article
Source: PubMed
Authors: K F Lai, Y M Wu, Z Luo, X H Fu, P Chen, Z W Zhao, L M Wang, C T Liu, Xu Xiao, Sofia Necander, Viktoria Werkström, David Cohen, Andrew Menzies-Gow, N S Zhong
Institutions: First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Xuzhou Central Hospital, First Affiliated Hospital of Kunming Medical University, Inner Mongolia Medical University, General Hospital of Shenyang Military Region, Guangzhou First People's Hospital, South China University of Technology, Westlake University, Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine, Sichuan University, AstraZeneca (United States), AstraZeneca (Sweden), AstraZeneca (United Kingdom)
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4415085661